Axsome Therapeutics is a clinical-stage biopharmaceutical company developing therapies for the management of central nervous system (CNS) disorders. Co.'s primary CNS portfolio includes five CNS product candidates: AXS-05, which is for the treatment of major depressive disorder, treatment resistant depression, agitation associated with Alzheimer's disease, and as an aid to smoking cessation; AXS-07, which is for the acute treatment of migraine; AXS-09, which is being developed for the treatment of CNS disorders; AXS-12, which is in development for the treatment of narcolepsy; and AXS-14, which is in development for the treatment of fibromyalgia. The AXSM stock yearly return is shown above.
The yearly return on the AXSM stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2018 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the AXSM annual return calculation with any dividends reinvested as applicable (on ex-dates).
|